Dat	e: 7. juni 2021		
You	r name : Rasmus Hvidbj	erg Gantzel	
Mai	nuscript title: Ularitide as tr	eatment of refractory ascites	in cirrhosis: A study protocol for a randomized trial
Mai	nuscript number (if knowr):	
are rothird committed to the committed t	elated to the content of your parties whose interests maitment to transparency a relationship/activity/interfollowing questions apply tous cript only.	our manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that you o the author's relationship vities/interests should be go	os/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript
antih In ite	ypertensive medication, e	ven if that medication is n port for the work reported	d declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months.
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial pla		
1			
	All support for the present		
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	None ADS AIPHIA Development Services AG, Switzerland.	PhD salary
	manuscript (e.g., funding, provision of study materials, medical writing,	None ADS AIPHIA Development	PhD salary
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	None ADS AIPHIA Development	PhD salary
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	None ADS AIPHIA Development	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	None ADS AIPHIA Development	PhD salary Click TAB in last row to add extra rows
Time	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	None ADS AIPHIA Development	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None ADS AIPHIA Development Services AG, Switzerland.	
Time	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None ADS AIPHIA Development	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	None ADS AIPHIA Development Services AG, Switzerland.	

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None
6	Payment for expert testimony	⊠ None
7	Support for attending meetings and/or travel	⊠ None
8	Patents planned, issued or pending	⊠ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None
11	Stock or stock options	⊠ None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None
13	Other financial or non- financial interests	⊠ None

🖾 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	e: 1. juli 2021		
You	r name: Markus Meyer		
Mar	nuscript title: Ularitide as	treatment of refractory ascite	es in cirrhosis: A study protocol for a randomized trial
Mar	nuscript number (if know	n):	
are rethird commits a The finant The aperta antih	elated to the content of y parties whose interests in itment to transparency relationship/activity/interests in itment to transparency relationship/activity/interestionship questions apply ascript only. Buthor's relationships/activity to the epidemiology properties are medication, m #1 below, report all sur	rour manuscript. "Related" may be affected by the con and does not necessarily in the rest, it is preferable that yet to the author's relationship ivities/interests should be of hypertension, you shoul even if that medication is result to the author's relationship in the rest of hypertension, you shoul even if that medication is result to the author's relation in the author's relationship in the author's r	ips/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript d declare all relationships with manufacturers of not mentioned in the manuscript.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial pl		THE STREET STREET STREET
1	All support for the present	□ None	
	manuscript (e.g., funding, provision of study materials, medical writing article processing charges etc.)	7.0	Consultant to ADS AIPHIA Development Services AG
	No time limit for this		
	item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from	⊠ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	⊠ None	

4 Consulting fees ADS AIPHIA Development Services AG Development Services AG	A
Development Services Development Services AG	A
AG	
5 Payment or honoraria for None	TO I
lectures, presentations,	
speakers bureaus,	
manuscript writing or	
educational events	
6 Payment for expert None	
6 Payment for expert	
Country	
7 Support for attending None	
meetings and/or travel	
8 Patents planned, issued or None	
pending	
9 Participation on a Data None	
Safety Monitoring Board or Advisory Board	
of Advisory Board	
10 Leadership or fiduciary None	
role in other board,	
society, committee or	
advocacy group, paid or	
unpaid	
11 Stock or stock options None	
LS HOILE	
12 Receipt of equipment, None	
materials, drugs, medical writing, gifts or other	
services	
13 Other financial or non-	
financial interests	

Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Dat	e: Kitk eller tryk for at angiv	e en dato. 8 th	me 202/
You	rname: NIELS K	RISTIAN MUI	me 2021 F FAGABRD
Ma			in cirrhosis: A study protocol for a randomized trial
Ma	nuscript number (if known):	
are rethird comillist a	elated to the content of yo parties whose interests m mitment to transparency a relationship/activity/intere	our manuscript. "Related" ay be affected by the con nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. ps/activities/interests as they relate to the current
perta antih In ite	ains to the epidemiology of sypertensive medication, e	hypertension, you should yen if that medication is n port for the work reporte	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plar		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
			Click TAB in last row to add extra row
Tim	e frame: past 36 months	THE REAL PROPERTY.	C. C. ST. LOS JOSE DE CONTRACTO
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	None	

4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non- financial interests	None

Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date:	Date: 1. juli 2021				
Your na	ame: Peter Jepsen				
Manuso	cript title: Ularitide as treatment of refractory ascites in cirrhosis: A study protocol for a randomized trial				
Manuso	cript number (if known):				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plan	ning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this item.		Click TAD in last you to odd out to your

Click TAB in last row to add extra rows

2	Grants or contracts from	⊠ None		
	any entity (if not indicated in item #1 above).	Novo Nordisk Foundation	I have a grant (paid to my institution) which buys me out from my clinical work to conduct a project entitled "Danish-English Collaboration to Combat Alcohol-related liver disease". The submitted work is not part of that project.	

3	Royalties or licenses	⊠ None
8.7		
	o liv s	
4	Consulting fees	⊠ None
_		
5	Payment or honoraria for lectures, presentations,	⊠ None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	⊠ None
	testimony	
7	Support for attending	⊠ None
	meetings and/or travel	TO TO THE STATE OF
8	Patents planned, issued or	⊠ None
	pending	Z None
9	Participation on a Data	⊠ None
	Safety Monitoring Board	THE STREET PERSON NEWSCOOL PROPERTY OF THE PROPERTY OF THE PERSON NAMED IN THE PERSON
	or Advisory Board	
10	Leadership or fiduciary	⊠ None
	role in other board, society, committee or advocacy group, paid or unpaid	
	and the second	
11	Stock or stock options	⊠ None
12	Receipt of equipment,	⊠ None
	materials, drugs, medical writing, gifts or other services	
4.7		
13	Other financial or non- financial interests	⊠ None
	mianciai mierests	

 $oxed{\boxtimes}$ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date	e : 1. juli 2021		
You	r name: Stefan Mazgare	eanu	
Mar	nuscript title: Ularitide as ti	eatment of refractory ascites	s in cirrhosis: A study protocol for a randomized trial
Mar	nuscript number (if knowr	n):	
are rethird commits a list a The firmant	elated to the content of your parties whose interests mentment to transparency a relationship/activity/interfollowing questions apply to uscript only.	our manuscript. "Related" hay be affected by the continuous not necessarily in rest, it is preferable that you to the author's relationship vities/interests should be gotten.	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. ps/activities/interests as they relate to the current defined broadly. For example, if your manuscript declare all relationships with manufacturers of
antih In ite	ypertensive medication, e m #1 below, report all sup	ven if that medication is n	ot mentioned in the manuscript. d in this manuscript without time limit. For all
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial pla		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	None ADS AIPHIA Development Services AG	Consultant to ADS AIPHIA Development Services AG
	No time limit for this item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		CHER THE ATTREET TO A CAST CALLED TOWN
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	■ None ADS AIPHIA Has received consulting fees from ADS AIPHIA	
		Development Services AG	Development Services AG
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	⊠None	
	testimony		
7	Support for attending	⊠None	
	meetings and/or travel		
		-4 -	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary	⊠ None	
	role in other board,	Miles-	
	society, committee or advocacy group, paid or		
	unpaid		
11	Stock or stock options	Ø None	
4.5		ref	
12	12 Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑ None	
13	Other financial or non-	⊠None	
	financial interests	- HOILE	

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal
Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish
Medical Journal.

Dat	e: 1. juli 2021			
You	ı r name : Johanne	es Holzn	neister	
Mai	nuscript title: Ulariti	de as tr	eatment of refractory ascites	s in cirrhosis: A study protocol for a randomized trial
Mai	nuscript number (if	known):	
are re third comr list a	elated to the conter parties whose inter mitment to transpar relationship/activit	nt of yo rests m rency a y/inter	our manuscript. "Related" ay be affected by the con nd does not necessarily in est, it is preferable that yo	
	ollowing questions uscript only.	apply t	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
perta antih In ite	nins to the epidemic sypertensive medica m #1 below, report	ology of ation, e	hypertension, you should ven if that medication is r	defined broadly. For example, if your manuscript d declare all relationships with manufacturers of not mentioned in the manuscript. d in this manuscript without time limit. For all months.
			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the ini	tial plar		ALL PRESENTS UNITED THE TOTAL PROPERTY OF
1	All support for the p manuscript (e.g., fur provision of study materials, medical w article processing ch etc.)	nding, vriting,	None ADS AIPHIA Development Services AG	Has provided the research grant to the University of Aarhus for funding of this clinical trial and has provided the investigational medicinal product
	No time limit for thi	is		
				Click TAB in last row to add extra rows
Time	e frame: past 36 mon	ths		
2	Grants or contracts any entity (if not ind in item #1 above).		⊠ None	
3	Royalties or licenses		⊠ None	

4	Consulting fees	⊠ None
5	Payment or honoraria for	⊠ None
3	lectures, presentations,	⊠ None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	⊠ None
	testimony	
7	Support for attending	⊠ None
	meetings and/or travel	₩ ivoile
Bui	meetings and or traver	
8	Patents planned, issued or	⊠ None
	pending	
9	Participation on a Data	⊠ None
9	Safety Monitoring Board	⊠ None
	or Advisory Board	
10	Leadership or fiduciary	⊠ None
	role in other board,	
	society, committee or	
	advocacy group, paid or	
	unpaid	
11	Stock or stock options	⊠ None
		WEST STREET, WHEN WEST STREET, WITH STREET, WAS ALLEGED AND STREET, WHEN STREET, WH
12	Receipt of equipment,	⊠ None
	materials, drugs, medical	
	writing, gifts or other services	
	services	
13	Other financial or non-	⊠ None
	financial interests	

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

You	e: 3. juni 2021 Ir name: Hugh WATS	DN	
			s in cirrhosis: A study protocol for a randomized trial
Mai	nuscript number (if kno	wn):	
		,	
are r third comi	elated to the content of parties whose interests nitment to transparenc	your manuscript. "Related" may be affected by the con	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	following questions appluscript only.	y to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
perta	ains to the epidemiology	of hypertension, you should	defined broadly. For example, if your manuscript declare all relationships with manufacturers of mentioned in the manuscript.
		upport for the work reporte for disclosure is the past 36	d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial p	The second secon	
1	All support for the prese manuscript (e.g., funding provision of study materials, medical writin article processing charge etc.)	g,	
	No time limit for this item.		
			Click TAB in last row to add extra rows
Tim	e frame: past 36 months		多原数医原生物 医肾盂炎 医外侧外
2	Grants or contracts from any entity (if not indicate in item #1 above).		
-			

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None
6	Payment for expert testimony	⊠ None
7	Support for attending meetings and/or travel	⊠ None
8	Patents planned, issued or pending	⊠ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None
11	Stock or stock options	Sanofi Stock
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None
13	Other financial or non- financial interests	⊠ None

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

	•		
Date	e: 3. juni 2021		
You	r name: Henning Grønba	æk	
Mai	nuscript title: Ularitide as tro	eatment of refractory ascites	s in cirrhosis: A study protocol for a randomized trial
Mai	nuscript number (if known):	
are rethird commiss a The finance The aperta antih	elated to the content of yo parties whose interests maitment to transparency at relationship/activity/interestions apply to uscript only. Buthor's relationships/activitys to the epidemiology of the epidemi	ur manuscript. "Related" ay be affected by the content does not necessarily in est, it is preferable that you the author's relationship vities/interests should be given if that medication is not port for the work reporter	ps/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript declare all relationships with manufacturers of not mentioned in the manuscript. d in this manuscript without time limit. For all
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plar		
1	All support for the present manuscript (e.g., funding,	None ADS AIPHIA Development	Study modication, DhD colony Pasmus Control study
	provision of study materials, medical writing, article processing charges,	Services AG, (Switzerland),	Study medication, PhD salary Rasmus Gantzel, study expenses
	etc.)		
	No time limit for this item.		
			Click TAB in last row to add extra row
			Click TAD III last TOW to add extra Tow
Time	e frame: past 36 months	at at the map family life	
2	Grants or contracts from	□ None	
	any entity (if not indicated	Abbvie	Research grant
	in item #1 above).	Intercept	Research grant
		ARLA	Research grant
3	Royalties or licenses	⊠ None	

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Norgine Norgine
6	Payment for expert testimony	⊠ None
7	Support for attending meetings and/or travel	⊠ None
8	Patents planned, issued or pending	⊠ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	Ipsen Advisory board
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None
11	Stock or stock options	⊠ None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None
13	Other financial or non- financial interests	⊠ None

Please place an "X" next to the following statement to indicate your agreement: 🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal